(Q41991133)

14 October 2017

Ipilimumab in patients with melanoma and autoimmune disease (English)

1 reference

14 October 2017

0 references

1 reference

3

Jedd D Wolchok

1 reference

14 October 2017

Chrisann Kyi

1

1 reference

14 October 2017

Richard D Carvajal

series ordinal

2

1 reference

14 October 2017

Michael A Postow

series ordinal

4

1 reference

14 October 2017

14 October 2014

1 reference

Journal for Immunotherapy of Cancer

14 October 2017

1 reference

14 October 2017

2

1 reference

14 October 2017

35

1 reference

14 October 2017

1

1 reference

Creative Commons Attribution 4.0 International

14 October 2017

start time

14 October 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/s40425-014-0035-z

0 references

cites work

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4207313

Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4207313

Melanoma in immunosuppressed patients

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4207313

Management of immune-related adverse events and kinetics of response with ipilimumab

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4207313

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4207313

2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4207313

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4207313

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4207313

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4207313

CTLA-4: a negative regulator of autoimmune disease.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4207313

Phase II study of extended-dose temozolomide in patients with melanoma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4207313

Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4207313

CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4207313

10.1186/S40425-014-0035-Z

3 November 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

14 October 2017

0 references

1 reference

14 October 2017

1 reference